董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| June Lee | 女 | Independent Director | 60 | 12.75万 | 0.49 | 2026-03-23 |
| Troy Ignelzi | 男 | Independent Director | 58 | 12.88万 | 0.49 | 2026-03-23 |
| Camilla Soenderby | 女 | Independent Director | 54 | 11.88万 | 0.49 | 2026-03-23 |
| Marc de Garidel | 男 | Chief Executive Officer and Director | 68 | 63.09万 | 49.91 | 2026-03-23 |
| Corinna zur Bonsen Thomas | 女 | Independent Director | 66 | 11.50万 | 2.13 | 2026-03-23 |
| Dominik Hchli | 男 | Independent Director | 58 | 8.63万 | 未持股 | 2026-03-23 |
| Camilla Soenderby | 女 | Independent Director | 54 | 未披露 | 未持股 | 2026-03-23 |
| Sylvie Grégoire | 女 | Board Chair and Independent Director | 64 | 14.38万 | 未持股 | 2026-03-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marc de Garidel | 男 | Chief Executive Officer and Director | 68 | 63.09万 | 49.91 | 2026-03-23 |
| Didier Blondel | 男 | Executive Vice President, Chief Financial Officer and Board Secretary | 63 | 未披露 | 6.74 | 2026-03-23 |
| Fabio Cataldi | 男 | Chief Medical Officer | 59 | 未披露 | 未持股 | 2026-03-23 |
董事简历
中英对照 | 中文 | 英文- June Lee
-
June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
June Lee has served as one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previoly served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as ll as management of staff, budget, and resce allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previoly served as a member of the board of directors of CinCor Pharma, Inc. and Renasant Bio. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis. - June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
- June Lee has served as one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previoly served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as ll as management of staff, budget, and resce allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previoly served as a member of the board of directors of CinCor Pharma, Inc. and Renasant Bio. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.
- Troy Ignelzi
-
Troy Ignelzi自2019年3月起担任我们的首席财务官。在此之前，Ignelzi先生于2016年3月至2019年2月担任ScpharmaceuticalsInc.首席财务官，并于2016年2月和3月为ScpharmaceuticalsInc.提供咨询服务。Ignelzi先生曾于2014年10月至2016年2月担任私营生物技术公司Juventas Therapeutics Inc.的首席财务官和执行领导团队成员。2013年10月至2014年10月，Ignelzi先生担任PharmAlex GmbH的运营和业务发展高级副总裁。在加入PharmAlex之前，Ignelzi先生于2009年1月至2013年9月在EsperionTherapeutics，Inc.（一家公共制药公司）Vice President业务开发。Ignelzi从2007年2月到2009年2月担任InsysTherapeutics，Inc.（一家专业制药公司）业务发展和战略规划Vice President。此前，Ignelzi从2002年2月到2005年8月担任Eli Lilly专业高级销售代表。Ignelzi先生拥有Ferris State University会计学士学位。
Troy Ignelzi has served as one of Abivax Sa independent directors since July 2023. Mr. Ignelzi has served as the Chief Financial Officer of Rapport Therapeutics, Inc. since October 2023. Prior to that, Mr. Ignelzi served as the Chief Financial Officer of Karuna Therapeutics, Inc. from March 2019 to October 2023 until its sale to Bristol Myers Squibb. Prior to his position at Karuna Therapeutics, Mr. Ignelzi was the Chief Financial Officer of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr. Ignelzi previoly served as Chief Financial Officer and as a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company, from October 2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice President—Operations and Biness Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice President—Biness Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January 2009 to September 2013. Mr. Ignelzi served as Vice President, Biness Development & Strategic Planning at Insys Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previoly, Mr. Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to Augt 2005. Mr. Ignelzi currently serves as a member of the board of directors of Contineum Therapeutics, Inc. and previoly served as a member of the board of directors of CinCor Pharma, Inc. and Vedanta Biosciences, Inc. Mr. Ignelzi has a B.S. in accounting from Ferris State University. - Troy Ignelzi自2019年3月起担任我们的首席财务官。在此之前，Ignelzi先生于2016年3月至2019年2月担任ScpharmaceuticalsInc.首席财务官，并于2016年2月和3月为ScpharmaceuticalsInc.提供咨询服务。Ignelzi先生曾于2014年10月至2016年2月担任私营生物技术公司Juventas Therapeutics Inc.的首席财务官和执行领导团队成员。2013年10月至2014年10月，Ignelzi先生担任PharmAlex GmbH的运营和业务发展高级副总裁。在加入PharmAlex之前，Ignelzi先生于2009年1月至2013年9月在EsperionTherapeutics，Inc.（一家公共制药公司）Vice President业务开发。Ignelzi从2007年2月到2009年2月担任InsysTherapeutics，Inc.（一家专业制药公司）业务发展和战略规划Vice President。此前，Ignelzi从2002年2月到2005年8月担任Eli Lilly专业高级销售代表。Ignelzi先生拥有Ferris State University会计学士学位。
- Troy Ignelzi has served as one of Abivax Sa independent directors since July 2023. Mr. Ignelzi has served as the Chief Financial Officer of Rapport Therapeutics, Inc. since October 2023. Prior to that, Mr. Ignelzi served as the Chief Financial Officer of Karuna Therapeutics, Inc. from March 2019 to October 2023 until its sale to Bristol Myers Squibb. Prior to his position at Karuna Therapeutics, Mr. Ignelzi was the Chief Financial Officer of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr. Ignelzi previoly served as Chief Financial Officer and as a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company, from October 2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice President—Operations and Biness Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice President—Biness Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January 2009 to September 2013. Mr. Ignelzi served as Vice President, Biness Development & Strategic Planning at Insys Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previoly, Mr. Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to Augt 2005. Mr. Ignelzi currently serves as a member of the board of directors of Contineum Therapeutics, Inc. and previoly served as a member of the board of directors of CinCor Pharma, Inc. and Vedanta Biosciences, Inc. Mr. Ignelzi has a B.S. in accounting from Ferris State University.
- Camilla Soenderby
-
Camilla Soenderby加入武田，担任首席患者价值和产品战略官。卡米拉曾于2018年3月加入夏尔，领导并监督全球产品战略，包括六大特许经营权、罕见疾病和特殊疾病以及全球市场准入、全球患者服务和全球商业运营。在加入夏尔之前，卡米拉是罗氏制药的地区负责人，负责中欧、南欧和东欧11个国家的盈亏。在此之前，她曾担任雅培（现在的雅培）的总经理，先是在瑞典，后来在英国。她还在先灵葆雅亚太区担任多个业务和战略角色，承担越来越大的责任，包括台湾地区总经理。卡米拉的职业生涯始于麦肯锡公司（McKinsey&Company），主要从事生物制药和医疗器械行业的管理顾问。
Camilla Soenderby has served as one of Abivax Sa independent directors since March 2024.Currently, Ms. Soenderby is a member of the Board of Directors for the investment company BB Biotech and the biotech company, F2G, and previoly served on the Board of Directors of the biotechnology company Affibody. In addition, she is a member of Novo Holdings Advisory Group and indtrial advisor for the private equity group EQT. Formally, Ms. Soenderby was a corporate officer at Takeda leading global portfolio commercialization in her role as Chief Patient Value and Product Strategy Officer for Takeda Pharmaceutical Co Ltd. Ms. Soenderby led and oversaw Global Product Strategy at Shire until its acquisition by Takeda. Prior t joining Shire, Ms. Soenderby was Region Head for Roche Pharma with profit and loss responsibility for 11 countries in Europe. Prior to that, she worked as General Manager for Abbott (now AbbVie), first for Sden and later for the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey & Company focing on the healthcare indtries. Ms. Soenderby holds a Master's degree from the University of Copenhagen. - Camilla Soenderby加入武田，担任首席患者价值和产品战略官。卡米拉曾于2018年3月加入夏尔，领导并监督全球产品战略，包括六大特许经营权、罕见疾病和特殊疾病以及全球市场准入、全球患者服务和全球商业运营。在加入夏尔之前，卡米拉是罗氏制药的地区负责人，负责中欧、南欧和东欧11个国家的盈亏。在此之前，她曾担任雅培（现在的雅培）的总经理，先是在瑞典，后来在英国。她还在先灵葆雅亚太区担任多个业务和战略角色，承担越来越大的责任，包括台湾地区总经理。卡米拉的职业生涯始于麦肯锡公司（McKinsey&Company），主要从事生物制药和医疗器械行业的管理顾问。
- Camilla Soenderby has served as one of Abivax Sa independent directors since March 2024.Currently, Ms. Soenderby is a member of the Board of Directors for the investment company BB Biotech and the biotech company, F2G, and previoly served on the Board of Directors of the biotechnology company Affibody. In addition, she is a member of Novo Holdings Advisory Group and indtrial advisor for the private equity group EQT. Formally, Ms. Soenderby was a corporate officer at Takeda leading global portfolio commercialization in her role as Chief Patient Value and Product Strategy Officer for Takeda Pharmaceutical Co Ltd. Ms. Soenderby led and oversaw Global Product Strategy at Shire until its acquisition by Takeda. Prior t joining Shire, Ms. Soenderby was Region Head for Roche Pharma with profit and loss responsibility for 11 countries in Europe. Prior to that, she worked as General Manager for Abbott (now AbbVie), first for Sden and later for the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey & Company focing on the healthcare indtries. Ms. Soenderby holds a Master's degree from the University of Copenhagen.
- Marc de Garidel
-
Marc de Garidel自2021年7月起担任我们的首席执行官和董事会成员。在被任命为我们的首席执行官之前，他于2020年9月至2021年4月担任AzTherapies，Inc.的首席执行官。de Garidel先生是AzTherapies，Inc.和Claris Biotherapics，Inc.的董事会成员。在2020年9月之前，de Garidel先生从2018年1月开始担任Corvidia Therapeutics，Inc.的首席执行官，直到2020年8月被Novo Nordisk A/S收购。de Garidel先生还于2010年11月至2016年7月担任Ipsen SA的首席执行官，并自2010年11月起担任Ipsen董事会主席。他的职业生涯始于1983年任职Eli Lilly Pharmaceutical Group，在那里他曾担任多种职务，并不断被提拔，随后于1995年加入安进公司，担任其欧洲首席财务官。De Garidel先生毕业于The Ecole SPé；Ciale des Travaux Publics，并在雷鸟全球管理学院获得国际管理硕士学位。
Marc de Garidel has served as Abivax Sa Chief Executive Officer since May 5, 2023 and Interim Chairman of the Board from May 5, 2023 to July 2024. He is currently the Chief Executive Officer and member of Abivax Sa Board and has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Beten July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Beten September 2020 and May 2021, Mr. de Garidel served as Chief Executive Officer of AZTherapies. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen beten November 2010 and July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in vario markets, including the United States and Europe. Mr. de Garidel has served as chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird Global School Management and an executive MBA from Harvard Biness School. - Marc de Garidel自2021年7月起担任我们的首席执行官和董事会成员。在被任命为我们的首席执行官之前，他于2020年9月至2021年4月担任AzTherapies，Inc.的首席执行官。de Garidel先生是AzTherapies，Inc.和Claris Biotherapics，Inc.的董事会成员。在2020年9月之前，de Garidel先生从2018年1月开始担任Corvidia Therapeutics，Inc.的首席执行官，直到2020年8月被Novo Nordisk A/S收购。de Garidel先生还于2010年11月至2016年7月担任Ipsen SA的首席执行官，并自2010年11月起担任Ipsen董事会主席。他的职业生涯始于1983年任职Eli Lilly Pharmaceutical Group，在那里他曾担任多种职务，并不断被提拔，随后于1995年加入安进公司，担任其欧洲首席财务官。De Garidel先生毕业于The Ecole SPé；Ciale des Travaux Publics，并在雷鸟全球管理学院获得国际管理硕士学位。
- Marc de Garidel has served as Abivax Sa Chief Executive Officer since May 5, 2023 and Interim Chairman of the Board from May 5, 2023 to July 2024. He is currently the Chief Executive Officer and member of Abivax Sa Board and has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Beten July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Beten September 2020 and May 2021, Mr. de Garidel served as Chief Executive Officer of AZTherapies. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen beten November 2010 and July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in vario markets, including the United States and Europe. Mr. de Garidel has served as chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird Global School Management and an executive MBA from Harvard Biness School.
- Corinna zur Bonsen Thomas
-
Corinna zur Bonsen Thomas在2022年8月至2023年5月期间担任Abivax Sa主席，自2017年6月起担任Abivax Sa独立董事之一。自2020年4月以来，Zur Bonsen-Thomas女士一直担任RetInSight GmbH的董事总经理兼首席执行官，该公司是她于2020年4月与他人共同创立的，专门从事眼科成像。Zur Bonsen-Thomas女士于2017年2月至2022年12月担任Smart Reporting GmbH的总法律顾问。1999年至2015年，她担任奥地利公司Baxter AG监事会成员。她在制药、生物制药、医疗和生物技术行业拥有超过三十年的国际专业经验。Zur Bonsen-Thomas女士在路德维希·马克西米利安大学参加了第一次法律州考试，在巴伐利亚州司法部参加了第二次法律州考试。
Corinna zur Bonsen Thomas served as Abivax Sa Chair beten August 2022 and May 2023 and has served as one of Abivax Sa independent directors since June 2017. Since April 2020, Ms. zur Bonsen Thomas has held the position of Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co founded in April 2020 and specializes in ophthalmic imaging. Ms. zur Bonsen Thomas was General Counsel for Smart Reporting GmbH from February 2017 to December 2022. From 1999 to 2015, she served as a member of the Supervisory Board of Baxter AG, an Atrian company. She has more than thirty years of international professional experience in the pharmaceutical, biopharmaceutical, medical and biotechnology indtries. Ms. zur Bonsen Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State Examination from the Bavarian Ministry of Jtice.industry. - Corinna zur Bonsen Thomas在2022年8月至2023年5月期间担任Abivax Sa主席，自2017年6月起担任Abivax Sa独立董事之一。自2020年4月以来，Zur Bonsen-Thomas女士一直担任RetInSight GmbH的董事总经理兼首席执行官，该公司是她于2020年4月与他人共同创立的，专门从事眼科成像。Zur Bonsen-Thomas女士于2017年2月至2022年12月担任Smart Reporting GmbH的总法律顾问。1999年至2015年，她担任奥地利公司Baxter AG监事会成员。她在制药、生物制药、医疗和生物技术行业拥有超过三十年的国际专业经验。Zur Bonsen-Thomas女士在路德维希·马克西米利安大学参加了第一次法律州考试，在巴伐利亚州司法部参加了第二次法律州考试。
- Corinna zur Bonsen Thomas served as Abivax Sa Chair beten August 2022 and May 2023 and has served as one of Abivax Sa independent directors since June 2017. Since April 2020, Ms. zur Bonsen Thomas has held the position of Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co founded in April 2020 and specializes in ophthalmic imaging. Ms. zur Bonsen Thomas was General Counsel for Smart Reporting GmbH from February 2017 to December 2022. From 1999 to 2015, she served as a member of the Supervisory Board of Baxter AG, an Atrian company. She has more than thirty years of international professional experience in the pharmaceutical, biopharmaceutical, medical and biotechnology indtries. Ms. zur Bonsen Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State Examination from the Bavarian Ministry of Jtice.industry.
- Dominik Hchli
-
Dominik H chli自2025年4月起担任Abivax SA独立董事之一。他既是临床和科学委员会的成员，也是商业委员会的成员。H chli博士在全球生物制药领域拥有超过20年的领导经验，最引人注目的是在艾伯维/雅培任职20年，在那里他担任免疫学全球营销副总裁，后来担任全球医疗事务主管。除了在艾伯维的工作经验外，H chli博士还在2021年至2024年期间担任血液肿瘤学公司Catapult Therapeutics的临时首席执行官。他还是制药战略咨询公司Abinode的创始人，目前在Molecular Partners AG担任董事会成员，担任审计委员会和研发委员会成员。H chli博士在瑞士伯尔尼大学获得医学学位（医学博士）。
Dominik Hchli has served as one of Abivax Sa independent directors since April 2025. He is a member of both the Clinical and Science Committee as ll as the Commercial Committee. In addition to his experience at AbbVie, Dr. Hchli served as Interim CEO of Catapult Therapeutics, a hematology oncology company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and currently serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit Committee and the Research & Development Committee. Dr. Hchli received his medical degree (M.D.) from the University of Bern in Switzerland. - Dominik H chli自2025年4月起担任Abivax SA独立董事之一。他既是临床和科学委员会的成员，也是商业委员会的成员。H chli博士在全球生物制药领域拥有超过20年的领导经验，最引人注目的是在艾伯维/雅培任职20年，在那里他担任免疫学全球营销副总裁，后来担任全球医疗事务主管。除了在艾伯维的工作经验外，H chli博士还在2021年至2024年期间担任血液肿瘤学公司Catapult Therapeutics的临时首席执行官。他还是制药战略咨询公司Abinode的创始人，目前在Molecular Partners AG担任董事会成员，担任审计委员会和研发委员会成员。H chli博士在瑞士伯尔尼大学获得医学学位（医学博士）。
- Dominik Hchli has served as one of Abivax Sa independent directors since April 2025. He is a member of both the Clinical and Science Committee as ll as the Commercial Committee. In addition to his experience at AbbVie, Dr. Hchli served as Interim CEO of Catapult Therapeutics, a hematology oncology company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and currently serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit Committee and the Research & Development Committee. Dr. Hchli received his medical degree (M.D.) from the University of Bern in Switzerland.
- Camilla Soenderby
-
Camilla Soenderby自2024年3月起担任Abivax SA独立董事之一。目前，Soenderby女士是投资公司BB Biotech和生物技术公司F2G的董事会成员，previoly则是生物技术公司Affibody的董事会成员。此外，她还是Novo Holdings Advisory Group的成员以及私募股权集团EQT的业内顾问。Soenderby女士正式担任武田领导全球产品组合商业化的公司官员，担任武田制药有限公司的首席患者价值和产品战略官。Soenderby女士在Shire领导和监督全球产品战略，直到其被武田收购。在加入Shire之前，Soenderby女士是罗氏制药的区域主管，负责欧洲11个国家的损益。在此之前，她曾在雅培（现为艾伯维）担任总经理，先是在斯登，后来在英国。她还在先灵葆雅亚太区担任过几个日益增加责任的运营和战略角色，包括台湾地区总经理。Soenderby女士的职业生涯始于麦肯锡公司的管理顾问，专注于医疗保健行业。Soenderby女士拥有哥本哈根大学硕士学位。
Camilla Soenderby has served as one of Abivax Sa independent directors since March 2024.Currently, Ms. Soenderby is a member of the Board of Directors for the investment company BB Biotech and the biotech company, F2G, and previoly served on the Board of Directors of the biotechnology company Affibody. In addition, she is a member of Novo Holdings Advisory Group and indtrial advisor for the private equity group EQT. Formally, Ms. Soenderby was a corporate officer at Takeda leading global portfolio commercialization in her role as Chief Patient Value and Product Strategy Officer for Takeda Pharmaceutical Co Ltd. Ms. Soenderby led and oversaw Global Product Strategy at Shire until its acquisition by Takeda. Prior to joining Shire, Ms. Soenderby was Region Head for Roche Pharma with profit and loss responsibility for 11 countries in Europe. Prior to that, she worked as General Manager for Abbott (now AbbVie), first for Sden and later for the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey & Company focing on the healthcare indtries. Ms. Soenderby holds a Master's degree from the University of Copenhagen. - Camilla Soenderby自2024年3月起担任Abivax SA独立董事之一。目前，Soenderby女士是投资公司BB Biotech和生物技术公司F2G的董事会成员，previoly则是生物技术公司Affibody的董事会成员。此外，她还是Novo Holdings Advisory Group的成员以及私募股权集团EQT的业内顾问。Soenderby女士正式担任武田领导全球产品组合商业化的公司官员，担任武田制药有限公司的首席患者价值和产品战略官。Soenderby女士在Shire领导和监督全球产品战略，直到其被武田收购。在加入Shire之前，Soenderby女士是罗氏制药的区域主管，负责欧洲11个国家的损益。在此之前，她曾在雅培（现为艾伯维）担任总经理，先是在斯登，后来在英国。她还在先灵葆雅亚太区担任过几个日益增加责任的运营和战略角色，包括台湾地区总经理。Soenderby女士的职业生涯始于麦肯锡公司的管理顾问，专注于医疗保健行业。Soenderby女士拥有哥本哈根大学硕士学位。
- Camilla Soenderby has served as one of Abivax Sa independent directors since March 2024.Currently, Ms. Soenderby is a member of the Board of Directors for the investment company BB Biotech and the biotech company, F2G, and previoly served on the Board of Directors of the biotechnology company Affibody. In addition, she is a member of Novo Holdings Advisory Group and indtrial advisor for the private equity group EQT. Formally, Ms. Soenderby was a corporate officer at Takeda leading global portfolio commercialization in her role as Chief Patient Value and Product Strategy Officer for Takeda Pharmaceutical Co Ltd. Ms. Soenderby led and oversaw Global Product Strategy at Shire until its acquisition by Takeda. Prior to joining Shire, Ms. Soenderby was Region Head for Roche Pharma with profit and loss responsibility for 11 countries in Europe. Prior to that, she worked as General Manager for Abbott (now AbbVie), first for Sden and later for the United Kingdom. She also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific, including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey & Company focing on the healthcare indtries. Ms. Soenderby holds a Master's degree from the University of Copenhagen.
- Sylvie Grégoire
-
Sylvie Grégoire自2024年7月起担任Abivax SA董事会主席和独立董事。Gr é goire博士是一位杰出的制药和生物技术高管，担任国际领导职务超过30年。她的专长包括后期开发、财务融资和商业扩张。Gr é goire博士是联合创始人，曾是位于马萨诸塞州波士顿的EIP Pharma Inc.的董事会执行主席。在她的领导下，EIP Pharma转型为在纳斯达克（CRVO）上市的公司CervoMed，开发出首个治疗路易体性痴呆的疾病修饰疗法。Gr é goire博士曾在Cubist、Glycofi、Vifor Pharma、Revvity、诺和诺德的董事会任职，并担任IDM Pharma、Corvidia和CervoMed的董事会主席。Gr é goire博士目前是CervoMed和F2G Ltd的董事会成员。Gr é goire博士拥有加拿大S é minaire de Sherbrooke的科学学院学位、加拿大拉瓦尔大学的药学学士学位以及纽约州立大学布法罗分校的药学博士学位。
Sylvie Grégoire has served as Chair of Abivax Sa Board and independent director since July 2024. Dr. Grégoire is a distinguished pharmaceutical and biotech executive with over 30 years in international leadership roles. Her expertise encompasses late stage development, financial raises and commercial expansion. Dr. Grégoire is the Co Founder and was Executive Chair of the Board at EIP Pharma Inc., based in Boston, MA. Under her leadership, EIP Pharma transitioned into CervoMed, a publicly listed company on NASDAQ (CRVO), developing the first disease moifying treatment for Dementia with Lewy Bodies. Dr. Grégoire has previoly served on the board of Cubist, Glycofi, Vifor Pharma, Revvity, Novo Nordisk and chaired the board of IDM Pharma, Corvidia and CervoMed. Dr. Grégoire is currently a member of the board of CervoMed and F2G Ltd. Dr. Grégoire holds a Science College degree from Séminaire de Sherbrooke in Canada, a BA in Pharmacy from Laval University in Canada, and a Pharmacy Doctorate degree from the State University of New York at Buffalo. - Sylvie Grégoire自2024年7月起担任Abivax SA董事会主席和独立董事。Gr é goire博士是一位杰出的制药和生物技术高管，担任国际领导职务超过30年。她的专长包括后期开发、财务融资和商业扩张。Gr é goire博士是联合创始人，曾是位于马萨诸塞州波士顿的EIP Pharma Inc.的董事会执行主席。在她的领导下，EIP Pharma转型为在纳斯达克（CRVO）上市的公司CervoMed，开发出首个治疗路易体性痴呆的疾病修饰疗法。Gr é goire博士曾在Cubist、Glycofi、Vifor Pharma、Revvity、诺和诺德的董事会任职，并担任IDM Pharma、Corvidia和CervoMed的董事会主席。Gr é goire博士目前是CervoMed和F2G Ltd的董事会成员。Gr é goire博士拥有加拿大S é minaire de Sherbrooke的科学学院学位、加拿大拉瓦尔大学的药学学士学位以及纽约州立大学布法罗分校的药学博士学位。
- Sylvie Grégoire has served as Chair of Abivax Sa Board and independent director since July 2024. Dr. Grégoire is a distinguished pharmaceutical and biotech executive with over 30 years in international leadership roles. Her expertise encompasses late stage development, financial raises and commercial expansion. Dr. Grégoire is the Co Founder and was Executive Chair of the Board at EIP Pharma Inc., based in Boston, MA. Under her leadership, EIP Pharma transitioned into CervoMed, a publicly listed company on NASDAQ (CRVO), developing the first disease moifying treatment for Dementia with Lewy Bodies. Dr. Grégoire has previoly served on the board of Cubist, Glycofi, Vifor Pharma, Revvity, Novo Nordisk and chaired the board of IDM Pharma, Corvidia and CervoMed. Dr. Grégoire is currently a member of the board of CervoMed and F2G Ltd. Dr. Grégoire holds a Science College degree from Séminaire de Sherbrooke in Canada, a BA in Pharmacy from Laval University in Canada, and a Pharmacy Doctorate degree from the State University of New York at Buffalo.
高管简历
中英对照 | 中文 | 英文- Marc de Garidel
Marc de Garidel自2021年7月起担任我们的首席执行官和董事会成员。在被任命为我们的首席执行官之前，他于2020年9月至2021年4月担任AzTherapies，Inc.的首席执行官。de Garidel先生是AzTherapies，Inc.和Claris Biotherapics，Inc.的董事会成员。在2020年9月之前，de Garidel先生从2018年1月开始担任Corvidia Therapeutics，Inc.的首席执行官，直到2020年8月被Novo Nordisk A/S收购。de Garidel先生还于2010年11月至2016年7月担任Ipsen SA的首席执行官，并自2010年11月起担任Ipsen董事会主席。他的职业生涯始于1983年任职Eli Lilly Pharmaceutical Group，在那里他曾担任多种职务，并不断被提拔，随后于1995年加入安进公司，担任其欧洲首席财务官。De Garidel先生毕业于The Ecole SPé；Ciale des Travaux Publics，并在雷鸟全球管理学院获得国际管理硕士学位。
Marc de Garidel has served as Abivax Sa Chief Executive Officer since May 5, 2023 and Interim Chairman of the Board from May 5, 2023 to July 2024. He is currently the Chief Executive Officer and member of Abivax Sa Board and has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Beten July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Beten September 2020 and May 2021, Mr. de Garidel served as Chief Executive Officer of AZTherapies. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen beten November 2010 and July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in vario markets, including the United States and Europe. Mr. de Garidel has served as chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird Global School Management and an executive MBA from Harvard Biness School.- Marc de Garidel自2021年7月起担任我们的首席执行官和董事会成员。在被任命为我们的首席执行官之前，他于2020年9月至2021年4月担任AzTherapies，Inc.的首席执行官。de Garidel先生是AzTherapies，Inc.和Claris Biotherapics，Inc.的董事会成员。在2020年9月之前，de Garidel先生从2018年1月开始担任Corvidia Therapeutics，Inc.的首席执行官，直到2020年8月被Novo Nordisk A/S收购。de Garidel先生还于2010年11月至2016年7月担任Ipsen SA的首席执行官，并自2010年11月起担任Ipsen董事会主席。他的职业生涯始于1983年任职Eli Lilly Pharmaceutical Group，在那里他曾担任多种职务，并不断被提拔，随后于1995年加入安进公司，担任其欧洲首席财务官。De Garidel先生毕业于The Ecole SPé；Ciale des Travaux Publics，并在雷鸟全球管理学院获得国际管理硕士学位。
- Marc de Garidel has served as Abivax Sa Chief Executive Officer since May 5, 2023 and Interim Chairman of the Board from May 5, 2023 to July 2024. He is currently the Chief Executive Officer and member of Abivax Sa Board and has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Beten July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Beten September 2020 and May 2021, Mr. de Garidel served as Chief Executive Officer of AZTherapies. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen beten November 2010 and July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in vario markets, including the United States and Europe. Mr. de Garidel has served as chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird Global School Management and an executive MBA from Harvard Biness School.
- Didier Blondel
Didier Blondel，自2017年1月起担任Abivax Sa 首席财务官兼董事会秘书。2012年1月至2016年12月，他在赛诺菲巴斯德MSD公司担任首席财务官，该公司是赛诺菲和默沙东在里昂成立的合资企业，也是欧洲人类疫苗的领导者。在此之前的20年里，Blondel先生在赛诺菲担任过多个高级财务职位，先是商业运营，然后是研发，后来成为全球研发首席财务官。他的职业生涯始于普华永道会计师事务所，毕业于法国顶尖商学院南锡商业学院，获得工商管理硕士学位。Blondel先生还拥有南锡二世大学的金融和会计硕士学位，以及金融和会计研究生文凭。
Didier Blondel has served as Abivax Sa Executive Vice President, Chief Financial Officer and Board Secretary since January 2017. From January 2012 to December 2016, he was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon based joint venture beten Sanofi and Merck and a European leader in human vaccines. Prior to that, over a 20 year period, Mr. Blondel held a wide range of senior finance positions at Sanofi, in Commercial Operations and then research and development, where he became global research and development Chief Financial Officer. He started his career as an auditor at PricewaterhoeCoopers, after graduating with a Master's degree in Biness and Administration from the Commercial Institute of Nancy, a leading French biness school. Mr. Blondel also holds a Master's degree in Finance and Accounting from Nancy II University, as ll as a Graduate Diploma in Finance and Accounting.- Didier Blondel，自2017年1月起担任Abivax Sa 首席财务官兼董事会秘书。2012年1月至2016年12月，他在赛诺菲巴斯德MSD公司担任首席财务官，该公司是赛诺菲和默沙东在里昂成立的合资企业，也是欧洲人类疫苗的领导者。在此之前的20年里，Blondel先生在赛诺菲担任过多个高级财务职位，先是商业运营，然后是研发，后来成为全球研发首席财务官。他的职业生涯始于普华永道会计师事务所，毕业于法国顶尖商学院南锡商业学院，获得工商管理硕士学位。Blondel先生还拥有南锡二世大学的金融和会计硕士学位，以及金融和会计研究生文凭。
- Didier Blondel has served as Abivax Sa Executive Vice President, Chief Financial Officer and Board Secretary since January 2017. From January 2012 to December 2016, he was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon based joint venture beten Sanofi and Merck and a European leader in human vaccines. Prior to that, over a 20 year period, Mr. Blondel held a wide range of senior finance positions at Sanofi, in Commercial Operations and then research and development, where he became global research and development Chief Financial Officer. He started his career as an auditor at PricewaterhoeCoopers, after graduating with a Master's degree in Biness and Administration from the Commercial Institute of Nancy, a leading French biness school. Mr. Blondel also holds a Master's degree in Finance and Accounting from Nancy II University, as ll as a Graduate Diploma in Finance and Accounting.
- Fabio Cataldi
Fabio Cataldi自2024年7月起担任Abivax SA首席医疗官。Cataldi博士在创新疗法的开发和商业化方面拥有超过20年的经验。他在免疫学和胃肠病学方面带来了深厚的临床、医疗和科学知识和专长，曾在阿里那制药、艾伯维、夏尔、辉瑞、TERM1、渤健和诺华担任高级研发职务。最近，他在Landos Biopharma担任首席营销官，直到成功出售给艾伯维。Cataldi博士目前管理Abivax SA临床运营、临床开发、药物警戒和医疗事务。Cataldi博士拥有Seconda Universit à degli Studi di Napoli的医学和外科医学博士学位。
Fabio Cataldi has served as Abivax Sa Chief Medical Officer since July 2024. Dr. Cataldi has over 20 years of experience in the development and commercialization of innovative therapies. Most recently, he held the role of CMO at Landos Biopharma until the successful sale to AbbVie. Dr. Cataldi currently manages Abivax Sa clinical operations, clinical development, pharmacovigilance and medical affairs. Dr. Cataldi holds an M.D. in Medicine and Surgery from the Seconda Università degli Studi di Napoli.- Fabio Cataldi自2024年7月起担任Abivax SA首席医疗官。Cataldi博士在创新疗法的开发和商业化方面拥有超过20年的经验。他在免疫学和胃肠病学方面带来了深厚的临床、医疗和科学知识和专长，曾在阿里那制药、艾伯维、夏尔、辉瑞、TERM1、渤健和诺华担任高级研发职务。最近，他在Landos Biopharma担任首席营销官，直到成功出售给艾伯维。Cataldi博士目前管理Abivax SA临床运营、临床开发、药物警戒和医疗事务。Cataldi博士拥有Seconda Universit à degli Studi di Napoli的医学和外科医学博士学位。
- Fabio Cataldi has served as Abivax Sa Chief Medical Officer since July 2024. Dr. Cataldi has over 20 years of experience in the development and commercialization of innovative therapies. Most recently, he held the role of CMO at Landos Biopharma until the successful sale to AbbVie. Dr. Cataldi currently manages Abivax Sa clinical operations, clinical development, pharmacovigilance and medical affairs. Dr. Cataldi holds an M.D. in Medicine and Surgery from the Seconda Università degli Studi di Napoli.